ReviewTranslational neurodegeneration2015
Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future.
Review in Translational neurodegeneration, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Effects of Music-Based Interventions on Motor and Non-Motor Symptoms in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2023Pooled it
- Phase 1/1b Studies of UCB0599, an Oral Inhibitor of α-Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2022Trial
- Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease.Journal of aerosol medicine and pulmonary drug delivery · 2018Trial
- Biomechanical energy harvesting to improve post-stroke mobility.Nature communications · 2026Article
- Parkinson's Disease: From Bench to Bedside-Advancements in Diagnosis and Therapeutics using Pharmacogenomic Approach.Current gene therapy · 2026Review
- Effect of Treatment of Hypokinetic Dysarthria in Parkinson's Disease with Speech and Language Therapy: A Meta-Analysis.Iranian journal of public health · 2025Review
- Personalized progression modelling and prediction in Parkinson's disease with a novel multi-modal graph approach.NPJ Parkinson's disease · 2024Article
- Recent updates on structural insights of MAO-B inhibitors: a review on target-based approach.Molecular diversity · 2024Review
- Evaluation and Application of a PET Tracer in Preclinical and Phase 1 Studies to Determine the Brain Biodistribution of Minzasolmin (UCB0599).Molecular imaging and biology · 2024Article
- Soft robotic apparel to avert freezing of gait in Parkinson's disease.Nature medicine · 2024Article
- Dopaminergic regulation of inflammation and immunity in Parkinson's disease: friend or foe?Clinical & translational immunology · 2023Review
- The PPN and motor control: Preclinical studies to deep brain stimulation for Parkinson's disease.Frontiers in neural circuits · 2023Review
- Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson's disease: Post-hoc analyses from a large 54-week trial.Clinical parkinsonism & related disorders · 2023Article
- Real-life benefits of intrajejunal levodopa infusion therapy in four patients with the parkinsonian variant of progressive supranuclear palsy: A 1-year follow-up data report.Brain and behavior · 2022Article
- Deep brain stimulation for Parkinson's Disease: A Review and Future Outlook.Biomedical engineering letters · 2022Review
- Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases.International journal of molecular sciences · 2021Review
- Article
- A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.Frontiers in neurology · 2021Article
- Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats.Psychopharmacology · 2020Article
- Gait Progression Over 6 Years in Parkinson's Disease: Effects of Age, Medication, and Pathology.Frontiers in aging neuroscience · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The problems associated with the pharmacological treatment of the later stages of Parkinson's disease (PD) remain those seen over many years. These centre on a loss of drug effect ('wearing off') with disease progression, the occurrence of dyskinesia, notably with L-dopa use and the appearance of non-motor symptoms that are largely refractory to dopaminergic medication. Treatment strategies in late PD have been dominated by the use of drug combinations and the subtle manipulation of drug dosage. However, change is occurring as the understanding of the basis of motor complications and fluctuations and non-motor symptoms improves. New pharmacological options are expanding with the advent of longer acting versions of existing dopaminergic drugs, new drug delivery systems and the introduction of non-dopaminergic agents able to manipulate motor function both within the basal ganglia and in other brain regions. Non-dopaminergic agents are also being investigated for the treatment of dyskinesia and for the relief of non-motor symptoms. However, while therapy continues to improve, the treatment of late stage PD remains problematic with non-motor symptoms dominating the unmet need in this patient group.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.